CLUSTER filed Aug 12, 2026 at 17:14 ET
Mirum Pharmaceuticals CEO Christopher Peetz and CFO Eric Bjerkholt sold a combined $1.75M in open-market stock within two days of the company's Q2 2026 earnings release, which showed strong 38% revenue growth but a significant GAAP EPS miss (-$1.06 vs -$0.75 consensus) and a key pipeline delay for volixibat. The CEO's sales ($1.98M total, including derivative exercises) and CFO's sale ($600K) represent ~0.03% of the $6.4B market cap, a trivial proportion that is likely liquidity-driven following option exercises rather than a bearish signal. The cluster is a net sell but the dollar amount is immaterial relative to company size, and the CEO's derivative exercise and same-day sale is a classic cashless exercise pattern, not an informed sell signal.